menu
    • menu
    [{"orgOrder":0,"company":"Clinigen Group","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Dexrazoxane","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ CNX Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ CNX Therapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexrazoxane","moa":"||Topoisomerase II","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Divestment","leadProduct":"Aldesleukin","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||G-CSF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"||Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Immunocore","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"||Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat","moa":"||Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Porton Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder for Solution","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Inapplicable","moa":"||Interferon-alpha\/beta-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Clinigen Group \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ Synairgen"}]

    Find Clinical Drug Pipeline Developments & Deals by Clinigen Group

    Menu

    Clinigen Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MaaT013,Vancomycin Hydrochloride

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : MaaT Pharma

                            Deal Size : $33.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg

                            Details : MaaT and Clinigen signed exclusive long-term licensing agreement and commercial supply agreement for Xervyteg (MaaT013), its first in class treatment proposed for patients with acute GVHD.

                            Product Name : Xervyteg

                            Product Type : Protein

                            Upfront Cash : $12.4 million

                            July 02, 2025

                            Lead Product(s) : MaaT013,Vancomycin Hydrochloride

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : MaaT Pharma

                            Deal Size : $33.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vamorolone,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Santhera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Santhera, Clinigen Sign Supply, Distribution Deal for AGAMREE® (Vamorolone)

                            Details : Under the agreement, Clinigen Group will supply and distribute Agamree (vamorolone) in countries where the product is not otherwise commercially available.

                            Product Name : Agamree

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Vamorolone,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Santhera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexrazoxane,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : CNX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics

                            Details : Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics...

                            Product Name : Totect

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 08, 2023

                            Lead Product(s) : Dexrazoxane,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : CNX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : $206.3 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Clinigen Divests Proleukin® to Iovance Biotherapeutics for £166.7 million

                            Details : Proleukin® (aldesleukin), a form of interleukin-2, is indicated for the treatment of adults with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC).

                            Product Name : Proleukin

                            Product Type : Protein

                            Upfront Cash : $206.3 million

                            January 23, 2023

                            Lead Product(s) : Aldesleukin,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : $206.3 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinigen Initiates A Managed Access Program For Relugolix In Europe For The Treatment Of Advanced Hormone-sens...

                            Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

                            Product Name : Orgovyx

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 20, 2022

                            Lead Product(s) : Relugolix,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Humanigen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Humanigen Launches Managed Access Program for Lenzilumab

                            Details : Humaneered (lenzilumab), is an investigational product that is not currently authorized or approved in any country, now available for certain hospitalized COVID-19 patients through its newly-launched LenzMAP.

                            Product Name : Humaneered

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 02, 2022

                            Lead Product(s) : Lenzilumab,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Humanigen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin,Riluzole

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinigen Notes Results from The MIROCALS Trial Investigating Low Dose Proleukin® (aldesleukin) In Patients wi...

                            Details : Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.

                            Product Name : Proleukin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 12, 2022

                            Lead Product(s) : Aldesleukin,Riluzole

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tebentafusp,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Immunocore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 14, 2021

                            Lead Product(s) : Tebentafusp,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Immunocore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anifrolumab,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anifrolumab Early Access Program

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 11, 2021

                            Lead Product(s) : Anifrolumab,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexrazoxane,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinigen’s Totect® Receives FDA Approval for New Indication to Treat Incidence and Severity of Cardiomyopat...

                            Details : Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.

                            Product Name : Totect

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 11, 2020

                            Lead Product(s) : Dexrazoxane,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth